Figure 1.

Different steps in the molecular scaffold construction: a) In vitro identification of a mimetic (IELLQAR) of a natural ligand (sLe^X ); b) Development of a highly substituted peptide/[60]fullerene hybrid; c) Multivalent and selective recognition of E‐selectin (dark‐teal receptors) by the fullerene hybrids, with the potential application of blocking the attachment of sLe^X ‐overexpressing circulating tumor cells (gray cells) to the activated endothelium (pink cells) with the subsequent inhibition of metastasis.